Bio-Path (BPTH) announced the receipt of newly issued patents in the United States and New Zealand, and updated investors on the extent of its ...

HOUSTON - Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotech firm focused on developing cancer and obesity treatments currently valued at $2.76 million, has announced the expansion of its intellectual ...

Scientists at the Garvan Institute of Medical Research have discovered that certain gene variations associated with leukemia ...

Cara Therapeutics has entered into a merger agreement with Tvardi Therapeutics to form a new Nasdaq-listed company focusing on developing STAT3 inhibitors to treat fibrosis-driven diseases.

To access the live and archived webcast, visit the News & Events page of the company’s website at https://recludixpharma.com/news-events. The archived webcast will be available for 30 days following ...

Through a combination of functional experiments and bioinformatics analyses, the researchers demonstrated that SMARCB1-deficient bladder tumors exhibit heightened activation of the IL6/JAK/STAT3 ...

Christopher Posner, President and CEO of Cara Therapeutics, Inc. (NASDAQ:CARA), recently sold 372 shares of the company's common stock. The shares were sold at a price range of $4.72 to $4.74, with ...